Loading TGTX detail
Loading ticker data...
Loading TGTX detail
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7. 1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A.
TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Chart data unavailable
Briumvi's US net product revenues reached $182.7M in Q4'25, with 19.5% sequential growth, and 2026 global revenue guidance is $875M–$900M. Key catalysts include the ENHANCE trial readout (mid-2026) and pivotal subcutaneous Briumvi data (year-end 2026/1Q 2027), both with significant upside potential. TGTX's $300M buyback program could provide downside support, although material negative updates are still a risk even with the buyback program in place.
JPMorgan Chase and Co. raised its holdings in TG Therapeutics, Inc. (NASDAQ: TGTX) by 56.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 227,934 shares of the biopharmaceutical company's stock after buying an additional 81,907 shares during the quarter. JPMorgan Chase and
Congress Asset Management Co. purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,922,410 shares of the biopharmaceutical company's stock, valued at approximately $57,307,000. Congress Asset Management Co.
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives
This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
TG Therapeutics, Inc. (NASDAQ: TGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company.
NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in people with highly active relapsing forms of multiple sclerosis (RMS). The article, authored by Hans-Peter Hartung, MD, of Heinrich Heine University Düsseldorf and colleagues, was published in Neurology and Therapy. The analysis evaluated efficacy outcomes in participants with highly active disease at baseline, defined as ≥2 relapses in the year prior and ≥1 gadolinium-enhancing (Gd+) T1 lesion at baseline. Results demonstrated statistically significant reductions in relapse rates and MRI activity, as well as significantly higher rates of no evidence of disease activity (NEDA-3), with BRIUMVI compared to teriflunomide. Additional details from the publication are included below.
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2026 annual meeting, being held April 18 - 22, 2026, in Chicago, Illinois. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below.
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the achievement of a clinical milestone under its license agreement with TG Therapeutics, Inc. (Nasdaq: TGTX). The milestone payment for azercabtagene zapreleucel (azer-cel) was triggered by progress of a Phase 1 clinical trial of azer-cel in progres.
TG Therapeutics (NASDAQ: TGTX) executives highlighted rapid revenue growth for BRIUMVI in 2025, expanding adoption in relapsing multiple sclerosis (RMS), and multiple upcoming clinical and regulatory catalysts during the company's fourth-quarter and year-end 2025 earnings call. BRIUMVI revenue growth and 2026 outlook Chairman and CEO Michael Weiss said 2025 was a "defining year," with the company
TG Therapeutics remains a "Strong Buy," driven by robust BRIUMVI revenue growth and ambitious expansion initiatives. The company reported $594 million in 2025 U.S. BRIUMVI sales, a 90% YoY increase, and guides for $825–$850 million in 2026. Key catalysts include the phase 3 ENHANCE study (consolidated dosing) and a self-administered subcutaneous BRIUMVI, both targeting significant market segments.
TG Therapeutics misses Q4 earnings estimates, but total revenues surge 78% y/y on strong Briumvi sales. The company reaffirms its 2026 revenue outlook.
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics (TGTX) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.15 per share a year ago.
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively
